Source: A joint meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research
Roxana S. Dronca, MD, and Lisa A. Kottschade, APRN, MSN, CNP, offer their expert insights into recent data on advanced melanoma presented at a joint meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research. Listen to what these experts have to say about combination therapy in the adjuvant setting for metastatic melanoma, real-world utilization of checkpoint inhibitor therapy, sequencing options for BRAF +/- MEK Inhibition following immunotherapy, and the management of rheumatological immune-related adverse events following treatment with checkpoint inhibitors.
|Available Credit:||1.50 AMA PRA Category 1 Credits™.|
|Opens:||February 28, 2018|
|Expires:||February 27, 2019|
Other Healthcare Providers